PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY , Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited  (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies ...
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Durable Complete Metabolic Response Ongoing Since November 2025 ...
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care
MELBOURNE, Australia , Aug. 28, 2026 /PRNewswire/ -- Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer ...
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Flexsys Narrows 6PPD Replacement to Two Final Molecules and Enters Cooperative Research and Development Agreement with U.S. Geological Survey for Independent Toxicity Testing
These two steps bring a 6PPD replacement closer to market, as federal scientists will conduct extensive aquatic toxicity testing - a critical step toward final molecule selection and commercialization ...
2026-08-27T    Biotechnology   Chemical 
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety ...
2026-08-27T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery ...
2026-08-27T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed ...
2026-08-27T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS
Now spanning ZEISS Retina and Cataract Workflows, the EVA NEXUS ™  ophthalmic surgical system from ZEISS comes in a cataract-only configuration, bringing a tailored approach to different surgical ...
2026-08-27T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
Highlights: ...
2026-08-27T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Countdown to BIOHK2026: World-Class Biotech Convention Prepares to Host Global Pavilions, Multi-Track Forums, and Signature Executive Networking
HONG KONG , Aug. 27, 2026 /PRNewswire/ -- As a premier global landmark in biotech, BIOHK2026 convenes international biotech hubs, cross-disciplinary industry forums, and high-impact networking events ...
2026-08-27T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.